# Biopharma Sponsor AI Trial-Eligibility Snapshot -- Executive Summary

**== SAMPLE / GENERIC EXAMPLE -- SYNTHETIC DATA ==**

**Snapshot:** CAI-PH-GEN-DEMO-[hash]
**Snapshot date:** 2026-07-22
**Format:** contrarianAI Independent-Verifier $499 Snapshot
**Attesting party:** Kevin Luddy, Principal, contrarianAI LLC

**Sample sponsor profile:** Mid-cap biopharma (~$500M-$5B market cap) running an oncology Phase III trial
**AI system audited:** trial-eligibility classifier (mock model version trial-eligibility-classifier-v2.8.1, training cutoff 2026-01-15)
**Audit period:** 90 days
**Screenings analyzed:** 4,969

---

## Overall Determination

**CATEGORY C -- INSUFFICIENT FOR ATTESTATION**

Multiple high-severity distributional-drift events detected in the trial-eligibility classifier across the audit period. Sponsor should not represent the trial-eligibility AI as 21 CFR Part 11-defensible or FDA-Diversity-Plan-compliant until named remediation completes.

---

## The One Sentence Your Sponsor's Regulatory Affairs Lead Will Care About

**The AI trial-eligibility classifier's ineligible_exclude lane rate for Cohort P3 (age 65+, 3+ comorbidities, minority representation) rose from 22% to 75% over the audit period -- a 53 percentage-point cohort-differential that occurred silently while the sponsor's Clinical Trial Management System (CTMS) dashboard showed enrollment velocity, screen-fail rate, and mean-eligibility-score all in normal range throughout.**

The shift is invisible in aggregate screening metrics (enrollment velocity, mean eligibility-exclusion score, model confidence, aggregate screen-fail rate). It is visible only through per-cohort distributional-shape analysis performed by an independent verifier operating on the trial-eligibility AI's output stream with a distinct model family and retention pipeline.

Under 21 CFR Part 11 Section 11.10 electronic-records retention + ICH E6(R3) essential-documents requirements, any AI-driven eligibility decision from the affected period is subject to preservation duty throughout the trial and the post-marketing horizon. The FDA Diversity Plan appendix commitment -- "does the sponsor monitor AI-driven eligibility decisions for representative-population parity across pre-specified subgroups?" -- now has a materially harder-to-answer shape for the next FDA Type C meeting, EMA scientific advice request, or IRB continuing-review submission.

---

## By The Numbers

**Detection:**
- 15 total drift events detected across the 90-day audit period
- 10 high-severity
- 5 medium-severity
- First drift day: Day 44 (post-baseline window)
- Cohort P3 (age 65+, 3+ comorbidities, minority representation) primary signal source

**Patient volume at potential misroute:**
- ~1,280 Cohort P3 screenings over the 45-day drift-window
- ~970 of those (76%) routed to ineligible_exclude lane vs baseline 22% expected
- Delta: ~680 potentially-excluded P3 patients who would have moved to further_screening / eligible_enroll under baseline-representative distribution

**Regulatory + business exposure ranges (public benchmarks):**
- **FDA CRL (Complete Response Letter) at NDA/BLA submission** for Diversity Plan deficit: pivotal-trial re-run cost **$10M-$100M+ per program** (public precedent: multiple oncology + neuro + CV programs 2023-2026)
- **DSMB safety-signal investigation** triggered by representative-population imbalance: 3-6 month enrollment pause; per-day cost of Phase III trial hold typically $50K-$500K depending on program burn
- **FDA Bioresearch Monitoring Program (BIMO) inspection Form 483 observation** for missing PCCP (Predetermined Change Control Plan) evidence: regulatory-hold + amended-submission-cycle cost typically $2M-$25M
- **EMA scientific advice non-conforming outcome** for equity-of-access deficit: EU market-access delay 12-24 months post-approval; opportunity cost typically $50M-$500M per program depending on indication
- **21st Century Cures Act Section 3013** representative-population failure: FDA-required post-marketing commitment (PMC) trial cost $5M-$50M+
- **IRB continuing-review adverse determination** for AI-driven eligibility bias: trial-site suspension; recruitment restart cost per site $250K-$1M

**Cost-benefit ratio:**
- Baseline Audit engagement ($2,500) = ~0.005% of the low-end FDA CRL re-run scenario
- Enterprise Attestation ($35-55K) = ~0.05% of the low-end FDA CRL re-run scenario
- Snapshot ($499) = below sponsor procurement threshold; tests the discipline before organizational commitment

---

## What Went Wrong (Executive Summary)

The trial-eligibility AI was trained on historical trial data through 2026-01-15. Deployed Day 1 of the audit period. Over the 90-day production run, two input distributions shifted silently and simultaneously:

- **Recruitment-mix shift:** community-partnership + referral-network outreach amplified Cohort P3 (age 65+, 3+ comorbidities, minority representation) share by 35% post-Day 45 as the sponsor executed against the trial's Diversity Plan commitment.
- **Real-world burden shift:** post-shift P3 patients presented with higher comorbidity counts, worse ECOG performance status, and more prior-therapy lines than the P3 training distribution -- exactly the real-world burden the FDA Diversity Plan Guidance instructs sponsors to include, and exactly the shape the historically-underrepresented population carries.

The AI was NOT retrained. Its baked-in P3-exclusion offset (+3 exclusion-score points, from historical P3-underrepresented training) compounded with the shifted-input mix. Result: P3 patients were systematically routed to the ineligible_exclude lane at 75% frequency vs the 22% baseline, without a single alarm firing on the sponsor's CTMS / EDC / eTMF dashboard.

**Standard tools stayed green.** The differential became visible only when a distributional-shape sensor was applied to the 90-day eligibility-decision history at the patient-cohort level.

---

## The Independent-Verifier Principle (Why This Matters)

> "The control plane cannot reside within the entity it is meant to regulate."

The sponsor's clinical-AI vendor (Deep 6 AI / TrialGPT / Antidote / Unlearn / QuantHealth / Owkin or any similar), the sponsor's CRO (IQVIA / Parexel / ICON / PPD / Syneos), the sponsor's EDC / eTMF / CTMS vendor (Veeva / Medidata / Oracle Clinical One / Castor), and the sponsor's internal Clinical Operations + Regulatory Affairs teams cannot attest their own outputs. Different model family for verification. Different retention pipeline. Different judgment.

This Snapshot is produced by contrarianAI as an independent third party. Sensor operates on the trial-eligibility AI's output stream only, distinct from the production model family, with a different mathematical basis (distributional-shape statistics vs gradient-boosted classifier) and a different retention pipeline.

---

## Regulatory Framework Applied

- 21 CFR Part 11 (Electronic Records + Electronic Signatures -- reproducibility requirements)
- FDA Guidance for Industry: Diversity Plans to Improve Enrollment (April 2022)
- FDA AI/ML SaMD Action Plan (2021, updates 2024-2026)
- FDA Predetermined Change Control Plan (PCCP) Draft Guidance (2023)
- ICH E6(R3) GCP -- Good Clinical Practice (Nov 2023, effective 2025-2026)
- ICH E8(R1) General Considerations for Clinical Studies (revised for AI-in-trials)
- ICH E9(R1) Statistical Principles (updates for AI-driven analyses 2026)
- EMA Reflection Paper on AI in Medicinal Product Lifecycle (2023) + EMA Concept Paper
- 21st Century Cures Act Section 3013 (Real-World Evidence + representative-population requirements)
- FDA CDER Center for Excellence in Regulatory Decision Science AI Framework
- HIPAA Section 164 (patient data privacy in AI training / inference)
- IRB Common Rule 45 CFR 46 (AI-driven eligibility decision review)

---

## What Kevin Ships At Each Tier

| Tier | Price | Timeline | Scope |
|------|-------|----------|-------|
| **Snapshot (THIS ARTIFACT SHAPE)** | **$499** | **3 days** | **1-page determination on any single AI system + 3 fix-first items** |
| Baseline Audit | $2,500 | 5 days | Gap map + measurable test + 30/60/90 roadmap on ONE AI surface |
| Full Diagnostic | $15,000 | 2-3 wks | Portfolio review across 3-5 AI systems + team session |
| **Enterprise Attestation** | **$35-55K** | **3-6 wks** | **Full 8-layer coverage + FDA / EMA / DSMB / IRB-facing signed statement** |

**Snapshot credit ($499) applies to Baseline or Enterprise upgrade within 30 days.**

Big-4-equivalent for the Enterprise tier: $200K-$1M+ (Deloitte / KPMG / EY / PwC clinical-AI advisory). Same deliverable outcome; different price + delivery model.

---

## Immediate Next Steps (30-day)

1. **Freeze or hold-for-investigator-review** all post-drift AI-generated eligibility decisions in Cohort P3 pending representative-population validation per FDA Diversity Plan Guidance
2. **Issue preservation-hold documentation** to all site EDCs, the eTMF vendor, and the AI-classifier host covering the AI-driven eligibility-decision record for the audit period (21 CFR Part 11 Section 11.10 + ICH E6(R3) essential-documents duty)
3. **Notify Chief Medical Officer + VP Regulatory Affairs + Clinical Operations lead + DSMB chair** of the identified drift + remediation-in-progress; update the trial's Diversity Plan appendix + PCCP change log
4. **Preserve all decision-record artifacts** + tool-call traces + model-version metadata for potential FDA Bioresearch Monitoring Program inspection, EMA scientific-advice, ICH E6(R3) essential-documents review, DSMB safety-signal investigation, or IRB continuing-review response
5. **Retrain trial-eligibility AI** on updated data reflecting current representative-population recruitment distribution (or, if retraining not feasible within trial timeline, hold P3 decisions for manual investigator review through trial conclusion)
6. **Add adaptive drift-monitoring** to production trial-eligibility pipeline (real-time per-cohort representative-population-differential monitoring, not just annual sponsor QA)

---

## Contact

**Kevin Luddy** -- Principal, contrarianAI LLC
Wilmington NC (Castle Hayne)
Cal: https://cal.com/kevin-luddy-0dlzuu
Landing: https://contrarianai-landing.onrender.com
Pharma-vertical Snapshot: https://contrarianai-landing.onrender.com/pharma-snapshot.html

---

**Snapshot retention key: [hash]**
**Signed:** Kevin Luddy, Principal, contrarianAI LLC
**Date:** 2026-07-22

---

*This one-pager summarizes the full Snapshot deliverable (see `ph_snapshot_report.md`). Full Snapshot includes 8-layer determination, counterparty-question rehearsal (sample decisions from Day 47 with cryptographic hash + reproducibility verification), 3 fix-first items scoped to your surface, and signed independent-verifier declaration. Snapshot credit applies to Baseline or Enterprise upgrade within 30 days.*

**== END OF SAMPLE -- YOUR ACTUAL $499 SNAPSHOT WILL LOOK STRUCTURALLY IDENTICAL BUT WITH YOUR SPONSOR'S DATA + AI SYSTEM + TRIAL PHASE + INDICATION + REGULATORY-FRAMEWORK-CITATIONS ==**